GlassScriptPhysician profile
Bridget Lynn Lee
NPI 1639445182
$2,231.82
in general payments reported to CMS, 2019-2025
32 companies · $868 in 2025
The $868 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.34 · 2022: $215 · 2023: $386 · 2024: $715 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.90 | 2021-2025 | |
| Pfizer INC. | $368.73 | 2023-2025 | |
| Novo Nordisk INC | $227.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.47 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $137.07 | 2023-2025 | Fasenra |
| Lilly USA, LLC | $103.37 | 2022-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.19 | 2023-2025 | Caplyta |
| Inspire Medical Systems, INC. | $74.38 | 2023 | Inspire |
| Axsome Therapeutics, INC. | $67.03 | 2025 | Auvelity, Symbravo |
| Seqirus USA INC | $49.40 | 2025 | Fluad, Flucelvax |
| Aimmune Therapeutics, INC. | $48.77 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $38.74 | 2023-2024 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $37.65 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $35.99 | 2023-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.18 | 2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.24 | 2022-2024 | Repatha, Otezla |
| Medtronic, INC. | $28.96 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $26.05 | 2022 | |
| Grifols USA, LLC | $21.42 | 2025 | Prolastin-C Liquid |
| Dexcom, INC. | $20.15 | 2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $19.79 | 2024 | Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $18.72 | 2024 | Livalo |
| Xeris Pharmaceuticals, INC. | $18.60 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $18.57 | 2025 | Rexulti |
| Eisai INC. | $17.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $17.72 | 2025 | Bexsero, Shingrix, Arexvy |
| Cleerly, INC. | $16.81 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Vbi Vaccine (Delaware) INC. | $14.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.46 | 2023 | Quviviq |
| Antares Pharma, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.